Oncology Research Editorial Office

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.088697 - 16 July 2026

Abstract This article has no abstract. More >

Chunwei Huang, Jingyi Kong, Hangxing Ren, Wanchen Zhang, Shi Jiang^*, Xianneng Sheng^*

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.085387 - 16 July 2026

Abstract HER2-positive breast cancer accounts for 15–20% of all breast cancer cases. Although the development of monoclonal antibodies (e.g., trastuzumab, pertuzumab), tyrosine kinase inhibitors (e.g., lapatinib, pyrotinib), and antibody-drug conjugates (e.g., T-DM1, trastuzumab deruxtecan) has greatly improved patient prognosis, primary or acquired resistance to anti-HER2 therapy remains a major clinical challenge, leading to treatment failure and disease progression. Recent research has elucidated diverse resistance mechanisms, including HER2 signaling pathway aberrations (such as receptor mutations, alternative splicing, and bypass activation), tumor microenvironment remodeling (involving immunosuppressive cells, metabolic reprogramming, and immune checkpoint molecules), and ADC-specific resistance (impaired internalization,… More >

Tingting Yang¹, Meng Guan¹, Xin Guan¹, Lihua Kang¹, Xiaomeng Wang¹, Yanjie Guan¹, Yang Yang², Wei Deng³, Guoxiang Wang^1,*

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.083563 - 16 July 2026

Abstract Background: Tumor-driven vascular remodeling is crucial for breast cancer metastasis; yet, the role of tumor-derived exosomal miRNAs in this process remains underexplored. This study aimed to investigate the clinical relevance and the underlying mechanism of breast cancer-derived exosomal miR-92b-3p in endothelial reprogramming. Methods: miR-92b-3p expression was evaluated in the TCGA cohort and clinical patient samples. The effects of exosomal miR-92b-3p from breast cancer cells on recipient human microvascular endothelial cells (HMVECs) were assessed using in vitro angiogenesis, migration, and permeability assays, alongside in vivo murine xenograft models. Mechanistic targets were validated via dual-luciferase and rescue experiments. Results: miR-92b-3p was… More >

Zixin Wan^1,2,#, Jingdan Quan^1,2,#, Yue Qiu^1,2, Zhiwei Zhang^1,2,*

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.082561 - 16 July 2026

Abstract Gastric cancer (GC) is one of the malignant tumors with high incidence and mortality worldwide. It has concealed early symptoms, poor prognosis for advanced patients, and limited efficacy of conventional treatments. Metabolic reprogramming is a core hallmark of cancer, among which amino acid metabolic reprogramming plays a critical regulatory role in the initiation and progression of GC. By linking intracellular energy supply, biosynthetic demands, and tumor microenvironment remodeling, it participates in immune escape, redox homeostasis maintenance, and therapeutic resistance. Dysregulation of key amino acids, including arginine, tryptophan, glutamine, branched-chain amino acids, serine/glycine, and aspartic acid,… More >

Juan Wu^1,2, Yue Wang³, Honglin Yan¹, Juanjuan Li², Chuntao Quan^4,*, Jingping Yuan^1,*, Shengrong Sun^2,*

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.081653 - 16 July 2026

Abstract Objectives: Despite the success of CDK4/6 inhibitors (CDK4/6i) in treating HR+/HER2- breast cancer (BC), some patients experience treatment failure due to CDK4/6i resistance. This study aimed to investigate whether targeting Aurora A kinase enhances CDK4/6 inhibitor sensitivity. Methods: An Abemaciclib-resistant cell line (MCF7AR) was developed by treating MCF7 cells with gradually increasing concentrations of Abemaciclib. We evaluated the relative protein levels of p-RB, p-Aurora A, Aurora A, and USP22 in cell cultures, animal tissues, and clinical samples. The effect of Aurora A inhibition on reversing CDK4/6i resistance was assessed using cell viability assays and tumor… More >

Cristian Cojocaru, Marcel Costuleanu^*, Ovidiu Rusalim Petriș, Ruxandra Cojocaru, Decebal Vasîncu, Elena Cojocaru

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.080024 - 16 July 2026

Abstract Lung cancer in individuals who have never smoked (LCINS) represents a clinically and biologically distinct subset of non–small cell lung cancer, driven predominantly by oncogenic alterations rather than tobacco-related mutagenesis. This review aims to summarize current and emerging targeted and immune-based therapeutic strategies in LCINS individuals. These patients present a molecular profile that differs substantially from tobacco-associated disease and has direct consequences for treatment selection. Evidence published over the past five years has clarified how these molecular features shape treatment response and resistance in this setting. Particular attention is given to tumors with alterations in… More >

Shijia Lu^1,#, Yanmin Wang^1,#, Han Zhang¹, Mengjia Yan¹, Mengdan Sang², Jinle Wang¹, Huaying Du³, Jinwen Sima³, Yiran Zhen², Xue Yang², Yutong Zhang¹, Hongwei Zhou^1,*

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.079988 - 16 July 2026

Abstract Proliferating Cell Nuclear Antigen (PCNA) is a core protein in DNA replication and repair. Its functional dysregulation drives tumorigenesis and therapeutic resistance, making it a critical anticancer target. However, the fundamental conflict between PCNA’s indispensable “guardian” function in normal cells and its hijacked “accomplice” role in cancer cells constitutes the central challenge for targeted intervention: how to eradicate tumors while avoiding severe toxicity to normal tissues. This review aims to systematically review the latest advances and translational dilemmas in the field of PCNA-targeted therapy. It outlines various intervention strategies, including small-molecule inhibitors, proteolysis-targeting chimeras, post-translational More > Graphic Abstract

Zhihao Wei^1,#, Jijie Cai^1,#, Sifen Wang^2,#, Yachen Li³, Libo Luo¹, Jun Chen¹, Fuyu Li¹, Hongyu Nie¹, Ke Gong^4,*, Manbo Cai^1,*

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.079281 - 16 July 2026

Abstract Breast cancer (BC) remains a leading cause of cancer-related mortality worldwide, and accumulating evidence suggests that tumor-associated microbiota may contribute to disease heterogeneity beyond host genetic and immune determinants. Advances in sequencing and multi-omics technologies have uncovered a reproducible intratumoral microbiome in BC, with distinct compositional patterns associated with molecular subtypes, clinicopathological features, and clinical outcomes. Alterations in specific microbial taxa have also been linked to tumor immune status, metastatic potential, and therapeutic sensitivity, underscoring their potential value in disease stratification and prognostic assessment. Although breast tissue represents a low-biomass environment, multiple studies employing stringent… More >

Jia Liu^1,2,#, Binqian Wang^1,#, Yannan Jin¹, Wenquan Chen¹, Ruohan Shi¹, Weijia Wang¹, Xiaojing Zhang¹, Yi Tan³, Zhongran Man³, Bo Hu¹, Lisen Zhu¹, Biao Zhang^3,*, Chongchan Bao^4,5,*, Gongsheng Jin^1,*

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.079137 - 16 July 2026

Abstract Backgrounds: Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with a unique tumor microenvironment, and while Programmed cell death protein 1/Programmed cell death ligand 1 (PD-1/PD-L1) blockade represents a standard immunotherapy, most patients develop primary or acquired resistance, with few alternative immunotherapeutic targets currently available. Therefore, we aimed to identify potential immune checkpoint-related molecules involved in TNBC-macrophage crosstalk, clarify the underlying molecular mechanism mediated by small extracellular vesicles (sEVs), and provide a theoretical basis for the future development of novel immunotherapeutic targets against TNBC. Methods: Single-cell RNA-sequencing (scRNA-seq) datasets for various breast cancer… More >

Lisa J. Frey^1,*, Nina Lache¹, Nikita D. Fischer¹, Niklas Rölz¹, Lisa Frey¹, Maximilian Haack¹, Gregor Duwe¹, Stefan Porubsky², Axel Haferkamp¹, Daniel-C. Wagner^2,3, Maximilian P. Brandt¹

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.078954 - 16 July 2026

Abstract Objectives: Squamous cell carcinoma (SCC) of the bladder is an aggressive histologic subtype with distinct clinical behavior and limited treatment options after platinum-based chemotherapy. This study aimed to evaluate potential therapeutic targets in bladder SCC. Methods: A retrospective cohort of 790 patients who underwent radical cystectomy for bladder cancer between 2011 and 2021 was screened to identify cases with histologically confirmed SCC. All SCC cases in the pathology department from 2003 to 2011 were also reviewed. Clinical and pathological data from 54 patients were analyzed. A tissue microarray (TMA) was constructed, and immunohistochemical (IHC) analyses… More >